Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats

Journal of Neurosurgery

Volumn 92, Issue 3, 2000, Pages 419-427

  Dimeco, Francesco ^b   Rhines, Laurence D ^b   Hanes, Justin ^b   Tyler, Betty M ^b   Brat, Daniel ^b   Torchiana, Elena ^b   Guarnieri, Michael ^b   Colombo, Mario P ^b   Pardoll, Drew M ^b   Finocchiaro, Gaetano ^b   Brem, Henry ^b   Olivi, Alessandro ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Brain neoplasm; Cytokine; Glioma; Immunotherapy; Interleukin 12; Rat

Indexed keywords

INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER IMMUNOTHERAPY; DRUG MECHANISM; FEMALE; GLIOSARCOMA; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033994579     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2000.92.3.0419     Document Type: Article

References (46)

1. Angiolillo A, Sgadari C, Tosato G: A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann NY Acad Sci 795:158-167, 1996
2. Black P: Brain tumors. (First of two parts.) N Engl J Med 324: 1471-1476, 1991
3. Brunda M, Luistro L, Hendrzak JA, et al: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother 17:71-77, 1995
4. Brunda M, Luistro L, Rumennik L, et al: Antitumor activity of interleukin-12 in preclinical models. Cancer Chemother Pharmacol 38 (Suppl):S16-S21, 1996
5. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor activity of interleukin-12 (IL-12) in a murine tumor model. Proc Am Assn Cancer Res 34:464, 1993
6. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and anti-metastatic activity of interleukin 12 against murine tumors. J Exp Med 178:1223-1230, 1993
7. Cavallo F, Signorelli P, Giovarelli M, et al: Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 89:1049-1058, 1997
8. Chan SH, Perussia B, Gupta JW, et al: Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173:869-879, 1991
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
10. Cohen J: IL-12 deaths: explanation and a puzzle. Science 270: 908, 1995
11. Colombo MP, Forni G: Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15:48-51, 1994
12. Colombo MP, Modesti A, Parmiani G, et al: Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 52: 4853-4857, 1992
13. Colombo MP, Vagliani M, Spreafico F, et al: Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 56:2531-2534, 1996
14. Deen DF, Chiarodo A, Grimm EA, et al: Brain tumor working group report on the 9th International Conference on brain tumor research and therapy. J Neurooncol 16:243-272, 1993
15. Fujiwara H, Hamaoka T: Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 38 (Suppl):S22-S26, 1996
16. Gately M, Desai BB, Wolitzky AG, et al: Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 147: 874-882, 1991
17. Gately MK, Warrier RR, Honasoge S, et al: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6:157-167, 1994
18. Gately MK, Woltizky AG, Quinn PM. et al: Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143:127-142, 1992
19. Hendrzak JA, Brunda MJ: Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest 72:619-637, 1995
20. Hsieh CS, Macatonia SE, Tripp CS, et al: Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549, 1993
21. Jean WC, Spellman SR, Wallenfriedman MA, et al: Interleukin-12-based immunotherapy against rat 9L glioma. Neurosurgery 42:850-857, 1988
22. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Kobayashi M, Fitz L, Ryan M, et al: Identification and purification of natural killer cell stimulatory (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827-845, 1989
24. Lotze MT, Zitvogel L, Campbell R, et al: Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann NY Acad Sci 795:440-454, 1996
25. Majewski S, Marczak M, Szmurlo A, et al: Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 106:1114-1118, 1996
26. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959
27. Marcel T, Grausz JD: The TMC worldwide gene therapy enrollment report, end 1996. Hum Gene Ther 8:775-800, 1997
28. Modesti A, Musiani P, Cortesina G, et al: Cytokine dependent tumor recognition, in Forni G, Foa R, Santoni A, et al (eds) Cytokine-Induced Tumor Immunogenicity: From Exogenous Molecules to Gene Therapy. London: Academic Press, 1994, pp 55-68
29. Mu J, Zou JP, Yamamoto N, et al: Administration of recombinant 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 55: 4404-4408, 1995
30. Nastala CL, Edington HD, McKinney TG, et al: Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153:1697-1706, 1994
31. Naume B, Gately M, Espevik T: A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ and NK cells. J Immunol 148:2429-2436, 1992
32. Noguchi Y, Richards EC, Chen YT, et al: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92:2219-2223, 1995
33. O'Toole M, Wolf SF, O'Brien C, et al: Effect of in vivo IL-12 administration on murine tumor cell growth. J Immunol 150 (Suppl):294A, 1993 (Abstract)
34. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
35. Roszman T, Elliott L, Brooks W: Modulation of T-cell function by gliomas. Immunol Today 12:370-374, 1991
36. Sarmiento UM, Riley JH, Knaack PA, et al: Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest 71:862-873, 1994
37. Stern AS, Podlaski FJ, Hulmes JD, et al: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87:6808-6812, 1990
38. Tada M, Diserens AC, Desbaillets I, et al: Analysis of cytokine receptor messenger RNA expression in human glioblastoma cells and normal astrocytes by reverse-transcription polymerase chain reaction. J Neurosurg 80:1063-1073, 1994
39. Tare NS, Bowen S, Warrier RW, et al: Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interferon Cytokine Res 15:377-383, 1995
40. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251-276, 1995
41. Vagliani M, Rodolfo M, Cavallo F, et al: Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res 56:467-470, 1996
42. Voest EE, Kenyon BM, O'Reilly MS, et al: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586, 1995
43. Watanabe M, McCormick KL, Volker K, et al: Regulation of local host-mediated anti-tumor mechanisms by cytokines. Direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol 150:1869-1880, 1997
44. Wong HL, Wilson DE, Jenson JC, et al: Characterization of a factor(s) which synergizes with recombinant interleukin-2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 111:39-54, 1988
45. Zitvogel L, Tahara H, Robbins PD, et al: Cancer immuno-therapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155: 1393-1403, 1995
46. Zou JP, Yamamoto N, Fujii T, et al: Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135-1145, 1995